阿托伐他汀与匹伐他汀调脂机制对比的研究进展

doi:10.12114/j.issn.1007-9572.2019.00.555

摘要/Abstract

摘要： 血脂异常尤其是胆固醇和/或三酰甘油（TG）水平的异常，已经成为促使动脉粥样硬化形成以及冠心病发生、发展的独立危险因素。我国血脂防治指南坚持将降低低密度脂蛋白胆固醇（LDL-C）水平作为预防动脉粥样硬化性心血管疾病（ASCVD）发生的首要干预靶点，将非高密度脂蛋白胆固醇（non-HDL-C）作为次要的干预靶点。目前，临床调脂达标的首选药物是他汀类药物，结构特点及代谢机制的不同使得他汀类药物具有差异性。本文将着重从化学结构、剂量、生物利用度、酶结合特性、组织穿透力和t1/2、代谢、消除、效力和调节胆固醇（主要是LDL-C）、TG及高密度脂蛋白胆固醇（HDL-C）机制等多个角度分析比较阿托伐他汀与匹伐他汀的异同点，为临床个体化用药提供理论依据。

关键词: 阿托伐他汀；匹伐他汀；降血脂药物；血脂异常；胆固醇；三酰甘油；胆固醇, LDL；胆固醇, HDL；综述

Abstract: Dyslipidemia，especially abnormal levels of cholesterol and/or triglycerides（TG），has become an independent risk factor of atherosclerosis and occurrence and development of coronary heart disease.Chinese guidelines for the prevention and treatment of blood lipid insist that lowering the level of low density lipoprotein cholesterol（LDL-C） is the primary intervention target for preventing atherosclerotic cardiovascular disease（ASCVD） and non-high density lipoprotei cholesterol（non-HDL-C） is the secondary intervention target.At present，the preferred drug for lipid regulation in clinical practice is statins，which may differ due to their different structural characteristics and metabolic mechanisms.This paper focused on the chemical structure，dosage，bioavailability，enzyme binding properties，tissue penetration and t1/2，metabolism，elimination，effectiveness and cholesterol regulation（mainly LDL-C），triglycerides and HDL-C mechanism to compare the similarities and differences between atorvastatin and pitavastatin，providing theoretical basis for clinical individualized medication.

Key words: Atorvastatin；Pitavastatin；Hypolipidemic agents；Dyslipidemias；Cholesterol；Triglycerides；Cholesterol, LDL；Cholesterol, HDL；Review

康晨瑜,王以新,冯妍,等. 阿托伐他汀与匹伐他汀调脂机制对比的研究进展[J]. 中国全科医学, 2020, 23(14): 1722-1728. DOI: 10.12114/j.issn.1007-9572.2019.00.555.
KANG Chenyu,WANG Yixin,FENG Yan, et al. Research Progress on the Comparison of Lipid Management Mechanism between Atorvastatin and Pitvastatin　[J]. Chinese General Practice, 2020, 23(14): 1722-1728. DOI: 10.12114/j.issn.1007-9572.2019.00.555.

参考文献

［1］ELMOWAFY M，IBRAHIM H M，AHMED M A，et al．Atorvastatin-loaded nanostructured lipid carriers（NLCs）：strategy to overcome oral delivery drawbacks［J］．Drug Deliv，2017，24（1）：932-941．DOI：10.1080/10717544.2017.1337823.
［2］CHAN P，SHAO L，TOMLINSON B，et al．An evaluation of pitavastatin for the treatment of hypercholesterolemia［J］．Expert Opin Pharmacother，2019，20（1）：103-113．DOI：10.1080/14656566.2018.1544243.
［3］AL MAMUN A，HASHIMOTO M，KATAKURA M，et al．Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-Leprcp/NDmcr rats，a metabolic syndrome model［J］．Biomed Pharmacother，2017，85：372-379．DOI：10.1016/j.biopha.2016.11.038.
［4］FU Z D，CUI J Y，KLAASSEN C D.Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice［J］．J Lipid Res，2014，55（12）：2576-2586．DOI：10.1194/jlr.M053124.
［5］HOEKE G，WANG Y N，VAN DAM A D，et al．Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis［J］．Atherosclerosis，2017，267：116-126．DOI：10.1016/j.atherosclerosis.2017.10.030.
［6］SAITO Y.Pitavastatin：an overview［J］．Atheroscler Suppl，2011，12（3）：271-276．DOI：10.1016/S1567-5688（11）70886-8.
［7］OHIRA M，ENDO K，SAIKI A，et al．Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase［J］．Metab Clin Exp，2012，61（10）：1452-1460．DOI：10.1016/j.metabol.2012.03.010.
［8］ARSENAULT B J，PETRIDES F，TABET F，et al．Effect of atorvastatin，cholesterol ester transfer protein inhibition，and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein（a） levels in patients at high cardiovascular risk［J］．J Clin Lipidol，2018，12（1）：130-136．DOI：10.1016/j.jacl.2017.10.001.
［9］ZHANG T.Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites［J］．Eur J Pharm Sci，2015，77：216-229．DOI：10.1016/j.ejps.2015.06.019.
［10］SCHONEWILLE M，DE BOER J F，MELE L，et al．Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice［J］．J Lipid Res，2016，57（8）：1455-1464．DOI：10.1194/jlr.M067488.
［11］SHIMIZU T，MIURA S，TANIGAWA H，et al．Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet［J］．Arterioscler Thromb Vasc Biol，2014，34（10）：2246-2253．DOI：10.1161/ATVBAHA.114.303715.
［12］YEE L L，WRIGHT E A.Pitavastatin calcium：clinical review of a new antihyperlipidemic medication［J］．Clin Ther，2011，33（8）：1023-1042．DOI：10.1016/j.clinthera.2011.07.011.
［13］ZHANG T.Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites［J］．Eur J Pharm Sci，2015，77：216-229．DOI：10.1016/j.ejps.2015.06.019.
［14］BLAHA M J，MARTIN S S.How do statins work?：changing paradigms with implications for statin allocation［J］．J Am Coll Cardiol，2013，62（25）：2392-2394．DOI：10.1016/j.jacc.2013.08.1626.
［15］HOEKE G，WANG Y N，VAN DAM A D，et al．Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis［J］．Atherosclerosis，2017，267：116-126．DOI：10.1016/j.atherosclerosis.2017.10.030.
［16］LIM S，SAKUMA I，QUON M J，et al．Differential metabolic actions of specific statins：clinical and therapeutic considerations［J］．Antioxid Redox Signal，2014，20（8）：1286-1299．DOI：10.1089/ars.2013.5531.
［17］SCHONEWILLE M，DE BOER J F，MELE L，et al．Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice［J］．J Lipid Res，2016，57（8）：1455-1464．DOI：10.1194/jlr.M067488.
［18］REDONDO-MORATA L，LEA SANFORD R，ANDERSEN O S，et al．Effect of statins on the nanomechanical properties of supported lipid bilayers［J］．Biophys J，2016，111（2）：363-372．DOI：10.1016/j.bpj.2016.06.016.
［19］BRUNENGRABER H.New mechanisms by which statins lower plasma cholesterol［J］．J Lipid Res，2016，57（8）：1325-1326．DOI：10.1194/jlr.C070417.
［20］THONGTANG N，DIFFENDERFER M R，OOI E M M，et al．
Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia：effects of rosuvastatin［J］．J Lipid Res，2017，58（7）：1315-1324．DOI：10.1194/jlr.M073882.
［21］HU M，TOMLINSON B.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins，rosuvastatin and pitavastatin［J］．Expert Opin Drug Metab Toxicol，2014，10（1）：51-65．DOI：10.1517/17425255.2014.851667.
［22］ZHANG H J，LAMON B D，MORAN G，et al．Pitavastatin differentially modulates microRNA-associated cholesterol transport proteins in macrophages［J］．PLoS One，2016，11（7）：e0159130．DOI：10.1371/journal.pone.0159130.
［23］ADAMS S P，SEKHON S S，WRIGHT J M.Lipid-lowering efficacy of rosuvastatin［J］．Cochrane Database Syst Rev，2014（11）：CD010254．DOI：10.1002/14651858.CD010254.pub2.
［24］OLIVEIRA K A，DAL-CIM T，LOPES F G，et al．Atorvastatin promotes cytotoxicity and reduces migration and proliferation of human A172 glioma cells［J］．Mol Neurobiol，2018，55（2）：1509-1523．DOI：10.1007/s12035-017-0423-8.
［25］SORAN H，LIU Y F，ADAM S，et al．A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes：results from the protection against nephropathy in diabetes with atorvastatin（PANDA） randomized trial［J］．J Clin Lipidol，2018，12（1）：44-55．DOI：10.1016/j.jacl.2017.10.011.
［26］BERWANGER O，SANTUCCI E V，DE BARROS E SILVA P G M，et al．Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome：the SECURE-PCI randomized clinical trial［J］．JAMA，2018，319（13）：1331-1340．DOI：10.1001/jama.2018.2444.
［27］ARSENAULT B J，PETRIDES F，TABET F，et al．Effect of atorvastatin，cholesterol ester transfer protein inhibition，and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein（a） levels in patients at high cardiovascular risk［J］．J Clin Lipidol，2018，12（1）：130-136．DOI：10.1016/j.jacl.2017.10.001.
［28］LI G M，ZHAO J，LI B，et al．The anti-inflammatory effects of statins on patients with rheumatoid arthritis：a systemic review and meta-analysis of 15 randomized controlled trials［J］．Autoimmun Rev，2018，17（3）：215-225．DOI：10.1016/j.autrev.2017.10.013.
［29］WARRAICH H J，SALAMI J A，KHERA R，et al．Trends in use and expenditures of brand-name atorvastatin after introduction of generic atorvastatin［J］．JAMA Intern Med，2018，178（5）：719-721．DOI：10.1001/jamainternmed.2018.0990.
［30］PENG S，XU L W，CHE X Y，et al．Atorvastatin inhibits inflammatory response，attenuates lipid deposition，and improves the stability of vulnerable atherosclerotic plaques by modulating autophagy［J］．Front Pharmacol，2018，9：438．DOI：10.3389/fphar.2018.00438.
［31］BODDE M C，WELSH P，BERGHEANU S C，et al．A rapid（differential） effect of rosuvastatin and atorvastatin on high-sensitivity cardiac troponin-Ⅰ in subjects with stable cardiovascular disease［J］．Clin Pharmacol Ther，2018，104（2）：311-316．DOI：10.1002/cpt.1095.
［32］PRATCHAYASAKUL W，THONGNAK L O，CHATTIPAKORN K，et al．Atorvastatin and insulin equally mitigate brain pathology in diabetic rats［J］．Toxicol Appl Pharmacol，2018，342：79-85．DOI：10.1016/j.taap.2018.01.021.
［33］FU N K，LIANG M，YANG S C.High loading dose of atorvastatin for the prevention of serum creatinine and cystatin C-based contrast-induced nephropathy following percutaneous coronary intervention［J］．Angiology，2018，69（8）：692-699．DOI：10.1177/0003319717750903.
［34］JIANG R C，ZHAO S G，WANG R Z，et al．Safety and efficacy of atorvastatin for chronic subdural hematoma in Chinese patients：a randomized clinical trial［J］．JAMA Neurol，2018，75（11）：1338-1346．DOI：10.1001/jamaneurol.2018.2030.
［35］BERTONE-JOHNSON E R，MANSON J E.Early menopause and subsequent cardiovascular disease［J］．Menopause，2015，22（1）：1-3．DOI：10.1097/GME.0000000000000385.
［36］COLOMBO A，MANGIERI A.Revascularization in 2017：technical and diagnostic improvements in PCI：more pieces in the puzzle［J］．Nat Rev Cardiol，2018，15（2）：80-82．DOI：10.1038/nrcardio.2017.205.
［37］SUGIURA T，AGARWAL R，TARA S，et al．Tropoelastin inhibits intimal hyperplasia of mouse bioresorbable arterial vascular grafts［J］．Acta Biomater，2017，52：74-80．DOI：10.1016/j.actbio.2016.12.044.
［38］ROSENSON R S，BREWER H B Jr，BARTER P J，et al．HDL and atherosclerotic cardiovascular disease：genetic insights into complex biology［J］．Nat Rev Cardiol，2018，15（1）：9-19．DOI：10.1038/nrcardio.2017.115.
［39］KOSKINAS K C，SIONTIS G C M，PICCOLO R，et al．Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention：a meta-analysis of randomized trials［J］．Eur Heart J，2018，39（14）：1172-1180．DOI：10.1093/eurheartj/ehx566.
［40］NISHIGUCHI T，KUBO T，TANIMOTO T，et al．Effect of early pitavastatin therapy on coronary fibrous-cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome：the ESCORT study［J］．JACC Cardiovasc Imaging，2018，11（6）：829-838．DOI：10.1016/j.jcmg.2017.07.011.
［41］DE WINTER R J，KATAGIRI Y，ASANO T，et al．A sirolimus-eluting bioabsorbable polymer-coated stent（MiStent） versus an everolimus-eluting durable polymer stent（Xience） after percutaneous coronary intervention（DESSOLVEⅢ）：a randomised，single-blind，multicentre，non-inferiority，phase 3 trial［J］．Lancet，2018，391（10119）：431-440．DOI：10.1016/S0140-6736（17）33103-3.
［42］RAGHOW R.Statins redux：a re-assessment of how statins lower plasma cholesterol［J］．World J Diabetes，2017，8（6）：230-234．DOI：10.4239/wjd.v8.i6.230.
［43］REDONDO-MORATA L，LEA SANFORD R，ANDERSEN O S，et al．Effect of statins on the nanomechanical properties of supported lipid bilayers［J］．Biophys J，2016，111（2）：363-372．DOI：10.1016/j.bpj.2016.06.016.
［44］MURTOLA T J，SYV?L? H，TOLONEN T，et al．Atorvastatin versus placebo for prostate cancer before radical prostatectomy——a randomized，double-blind，placebo-controlled clinical trial［J］．Eur Urol，2018，74（6）：697-701．DOI：10.1016/j.eururo.2018.06.037.
［45］KONG Y，CAO X N，ZHANG X H，et al．Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients［J］．Blood，2018，131（11）：1219-1233．DOI：10.1182/blood-2017-09-807248.
［46］MARELLI C，LAMARI F，RAINTEAU D，et al．Plasma oxysterols：biomarkers for diagnosis and treatment in spastic paraplegia type 5［J］．Brain，2018，141（1）：72-84．DOI：10.1093/brain/awx297.
［47］WATTS G F，CHAN D C，SOMARATNE R，et al．Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein（a） particle kinetics［J］．Eur Heart J，2018，39（27）：2577-2585．DOI：10.1093/eurheartj/ehy122.
［48］VALLEJO-VAZ A J，FAYYAD R，BOEKHOLDT S M，et al．Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial［J］．Circulation，2018，138（8）：770-781．DOI：10.1161/CIRCULATIONAHA.117.032318.